GlassScriptPhysician profile
Kerry Rut
NPI 1831413368
$4,749.34
in general payments reported to CMS, 2019-2025
32 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $444 · 2021: $518 · 2022: $1,114 · 2023: $694 · 2024: $454 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.11 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,259.57 | 2019-2024 | Lo Loestrin Fe, Orilissa, Liletta |
| Exeltis, USA INC. | $608.50 | 2020-2025 | Slynd |
| Evofem Biosciences, INC. | $450.63 | 2021-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $353.72 | 2019-2020 | |
| Myovant Sciences INC. | $351.85 | 2021-2022 | |
| Lupin INC. | $198.15 | 2019-2021 | |
| Astellas Pharma US INC | $154.62 | 2023-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $126.69 | 2021 | |
| Glaxosmithkline, LLC. | $117.99 | 2021 | |
| Sage Therapeutics, LLC | $113.63 | 2019 | |
| Pfizer INC. | $108.76 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $106.46 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $97.86 | 2019-2023 | Balcoltra |
| Mayne Pharma Commercial LLC | $95.46 | 2021-2024 | |
| Scynexis, INC. | $86.28 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $62.17 | 2025 | Femlyv |
| Daiichi Sankyo INC. | $60.11 | 2019-2020 | |
| Therapeuticsmd, INC. | $53.64 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $46.79 | 2019-2020 | |
| Allergan, INC. | $38.15 | 2019 | |
| Vertical Pharmaceuticals, LLC | $35.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.80 | 2019 | |
| Scilex Pharmaceuticals INC. | $33.26 | 2023 | Elyxyb, Ztlido |
| Shield Therapeutics INC | $22.96 | 2023 | Accrufer |
| Agile Therapeutics, INC. | $20.36 | 2023 | Twirla |
| Organon LLC | $19.13 | 2024 | |
| Roche Diagnostics Corporation | $18.16 | 2019 | |
| Hologic Sales and Service, LLC | $17.03 | 2019 | |
| Duchesnay USA Incorporated | $16.34 | 2019 | |
| Coopersurgical, INC. | $14.76 | 2020 | |
| Mission Pharmacal Company | $13.94 | 2019 | |
| Dysis Medical, INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Rut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.